Ascendis Pharma (ASND) Could Be 17% Below Fair Value Following Its TransCon Narrative
Ascendis Pharma (NasdaqGS:ASND) has drawn fresh investor attention after recent trading left the stock around $254.44, with short term returns mixed over the past week, month and past three months.
See our latest analysis for Ascendis Pharma.
Over a longer stretch, Ascendis Pharma has seen a 10.93% 90 day share price return and a 3.69% year to date share price return. The recent 30 day decline of 3.51% suggests some of that momentum has cooled even as the stock holds near US$254.44.
If this kind of move has you thinking about where else growth stories might emerge in healthcare, it could be worth scanning 40 healthcare AI stocks as a way to spot other potential opportunities in the sector.
Bulls point to Ascendis Pharma’s growing revenue base and late stage pipeline, while bears focus on the recent 30 day pullback and valuation risk near US$254.44. Which side does the current evidence lean toward as you weigh the stock’s value?
Most Popular Narrative: 16.5% Undervalued
The most followed narrative on Ascendis Pharma pegs fair value around $304.60, above the recent $254.44 close, and builds that gap around its TransCon endocrine portfolio.
Ascendis Pharma focuses on developing and commercializing long acting therapies for rare endocrine and growth disorders using its TransCon technology platform.
Broader adoption of YORVIPATH in chronic hypoparathyroidism, with only a small share of eligible U.S. patients currently on therapy and access expanding across more than 30 countries, can widen the treated patient base and support recurring product revenue and operating cash flow.
Want to see what sits behind that valuation gap on Ascendis Pharma? The narrative leans heavily on rapid top line growth, robust margins and a future earnings multiple that assumes sustained commercial execution. It is worth examining which specific revenue and profit targets, discount rate and share count assumptions would need to hold for $304.60 to be supported on a 3 year and 5 year view.
Result: Fair Value of $304.60 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Ascendis Pharma still faces key risks, including potential setbacks in TransCon CNP approvals and the possibility that product revenue may not keep pace with rising commercial costs.
Find out about the key risks to this Ascendis Pharma narrative.
Another View: What Ascendis Pharma’s P/E Is Telling You
There is a different story if you look at Ascendis Pharma through simple earnings multiples. The stock trades on a P/E of 29.7x, higher than the US Biotechs average of 17x but below peers at 40.9x. That mix of premium and discount raises a clear question: Is this price giving you enough margin for error?
To pressure test that question against the earnings multiple, it is worth examining what the numbers imply about future growth, profitability and re rating risk in more detail. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals around Ascendis Pharma so far, it makes sense to move fast and review the numbers yourself before sentiment shifts again. To weigh both sides of the story, start with the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Ascendis Pharma?
If Ascendis Pharma has sharpened your focus on quality, do not stop here. Use these screeners to spot other stocks that could fit your playbook today.
- Target potential mispricing by checking stocks that screen as high quality and potentially cheap through the 49 high quality undervalued stocks.
- Prioritise resilience by scanning companies with stronger balance sheets and steadier fundamentals using the solid balance sheet and fundamentals stocks screener (48 results).
- Get ahead of the crowd by reviewing the screener containing 20 high quality undiscovered gems and seeing which lesser known stocks still show solid underlying numbers.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com